-
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
22 Apr 2024 10:37 GMT
… the Parke-Davis division of Warner-Lambert and has previously served on … .
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on … Company anticipates submitting a new drug application to the U.S …
-
The City of New York v. Henriquez
23 Apr 2024 10:40 GMT
… first place. Bernard v. Com. Drug Co., 964 F.2d 1338 … 124 (quoting Nabisco, Inc. v. Warner-Lambert Co., 220 F.3d 43 …
-
Sermonix Pharmaceuticals Announces MBC Alliance Membership, New ‘Discover ELAINE’ Website
12 Feb 2024 14:00 GMT
… “Lasofoxifene, our lead investigational drug, has demonstrated both potential … , has extensive experience in pharmaceutical drug commercialization. Simon Jenkins, Ph … both Parke-Davis Pharmaceuticals and Warner-Lambert’s Pharmaceutical Division. Learn more …
-
Legendary local biostatistician Dr. Karl Peace: When drug approvals hit close to home
02 Feb 2024 19:52 GMT
… further clinical investigation by Warner-Lambert/Parke-Davis. … challenge without equal in pharmaceutical research and development. … IND (Investigational New Drug) to Warner Lambert/Parke-Davis … and management in the pharmaceutical industry. He held …
-
Sermonix to Host KOL Fireside Chat on Advancements in the Metastatic Breast Cancer Treatment Landscape on April 22, 2024
19 Apr 2024 20:26 GMT
… lasofoxifene, its lead investigational drug. The Sermonix management team, … , has extensive experience in pharmaceutical drug commercialization. Simon Jenkins, Ph … of both Parke-Davis Pharmaceuticals and Warner-Lambert’s Pharmaceutical Division. Learn more …
-
Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient Quality of Life
12 Dec 2023 22:15 GMT
… “Lasofoxifene, our lead investigational drug, has thus far demonstrated … , has extensive experience in pharmaceutical drug commercialization. Simon Jenkins, Ph … both Parke-Davis Pharmaceuticals and Warner-Lambert’s Pharmaceutical Division. Learn more …
-
Sermonix Pharmaceuticals Announces Publication of ELAINE-1 and ELAINE-2 Trial Results in Annals of Oncology
11 Dec 2023 23:05 GMT
… lasofoxifene, its lead investigational drug. The Sermonix management team, … , has extensive experience in pharmaceutical drug commercialization. Simon Jenkins, Ph … of both Parke-Davis Pharmaceuticals and Warner-Lambert’s Pharmaceutical Division. Learn more …
-
Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 Mutations
12 Dec 2023 14:00 GMT
… , suggesting little to no drug-drug interaction.
Abemaciclib concentrations in … , has extensive experience in pharmaceutical drug commercialization. Simon Jenkins, Ph … of both Parke-Davis Pharmaceuticals and Warner-Lambert’s Pharmaceutical Division. Learn more …
-
Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium
28 Nov 2023 14:01 GMT
… lasofoxifene, its lead investigational drug. The Sermonix management team, … , has extensive experience in pharmaceutical drug commercialization. Simon Jenkins, Ph … of both Parke-Davis Pharmaceuticals and Warner-Lambert’s Pharmaceutical Division. Learn more …
-
Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial
06 Nov 2023 14:00 GMT
… lasofoxifene, its lead investigational drug. The Sermonix management team, … , has extensive experience in pharmaceutical drug commercialization. Simon Jenkins, Ph … of both Parke-Davis Pharmaceuticals and Warner-Lambert’s Pharmaceutical Division. Learn more …